ResMed Inc (RMD) Releases 2025 Product Pipeline Analysis to Enhance Market Decision-Making
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Product Pipeline Overview: The 2025 Product Pipeline Analysis report released by ResMed details its major products in respiratory disorder management, including CPAP and VPAP devices, aimed at enhancing market competitiveness and addressing the growing health demands.
- Market Distribution Strategy: The company distributes its medical devices across various countries through a combination of distributors and direct sales teams, ensuring broad product coverage and strengthening partnerships with sleep clinics and home healthcare dealers to further expand market share.
- Software Service Innovation: ResMed also offers software as a service (SaaS) to out-of-hospital health providers, which not only enhances customer service efficiency but also creates new revenue streams, bolstering its competitive edge in the medical device industry.
- Decision Support Tool: The report provides key data and analysis for decision-makers, aiding in the formulation of effective counter-strategies to gain competitive advantage, reflecting the company's strategic adaptability in the rapidly changing healthcare market.
Analyst Views on RMD
Wall Street analysts forecast RMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMD is 302.56 USD with a low forecast of 270.00 USD and a high forecast of 335.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 243.080
Low
270.00
Averages
302.56
High
335.00
Current: 243.080
Low
270.00
Averages
302.56
High
335.00
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
